Dr yu lu9/1/2023 ![]() (HKSE: 2251), a global leader and pioneer in providing AI-empowered retina-based early detection, auxiliary diagnosis and health risk assessment solutions, on its US$215 million global offering and listing on The Stock Exchange of Hong Kong Limited ![]() (HKSE: 1228), a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of biotech therapies, on The Stock Exchange of Hong Kong Limited on December 10, 2021
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |